Dual-target CAR T-cell therapy shows durable remission in pediatric leukemia trial

A phase 2 nonrandomized trial evaluated bicistronic CD19/CD22 CAR T-cell therapy in 261 pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia across 5 centers in China. The trial reported that 99.2% achieved minimal residual disease-negative complete remission, with 24-month event-free survival of 63.2%, and found that consolidative transplant was associated with improved 24-month event-free survival (85.7% vs 57.9% without transplant). Grade 3 to 4 cytokine release syndrome occurred in 49.4% of patients and neurotoxic effects in 13.0%; the authors state these findings support further evaluation in prospective trials.

Most relevant for: Pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia, including those with isolated central nervous system or testicular relapse.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.